Skip to main content

1 Result(s)

within M. Merger Remove this filter Drug Resistance Remove this filter

and

  1. Article

    Open Access

    A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

    BI 2536, a novel Polo-like kinase 1 inhibitor, was assessed in patients with unresectable advanced exocrine adenocarcinoma of the pancreas.

    K Mross, C Dittrich, W E Aulitzky, D Strumberg, J Schutte… in British Journal of Cancer (2012)

    Download PDF (426 KB) View Article